within Pharmacolibrary.Drugs.ATC.G;

model G03AA06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.64,
    Cl             = 6.666666666666667e-07,
    adminDuration  = 600,
    adminMass      = 0.3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03AA06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Norgestrel and ethinylestradiol is a combination oral contraceptive containing a synthetic progestin (norgestrel) and a synthetic estrogen (ethinylestradiol), primarily used for the prevention of pregnancy. This combination is approved and widely used globally for birth control purposes. It may also be used for menstrual regulation in women.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reflect healthy adult female volunteers, typically of reproductive age, after administration of a single oral dose corresponding to a standard tablet (norgestrel 0.3 mg and ethinylestradiol 0.03 mg).</p><h4>References</h4><ol><li><p>Moreira de Brito, C, et al., &amp; Cercato, C (2021). Pharmacokinetics of oral levonorgestrel and ethinylestradiol in women after Roux-en-Y gastric bypass surgery. <i>Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery</i> 17(4) 673–681. DOI:<a href=&quot;https://doi.org/10.1016/j.soard.2020.12.007&quot;>10.1016/j.soard.2020.12.007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33547015/&quot;>https://pubmed.ncbi.nlm.nih.gov/33547015</a></p></li><li><p>Jordy, AB, et al., &amp; Bækdal, TA (2021). Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. <i>Clinical pharmacokinetics</i> 60(9) 1171–1185. DOI:<a href=&quot;https://doi.org/10.1007/s40262-020-00976-x&quot;>10.1007/s40262-020-00976-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33782832/&quot;>https://pubmed.ncbi.nlm.nih.gov/33782832</a></p></li><li><p>Zimmerman, Y, et al., &amp; Fauser, BC (2013). The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive. <i>The European journal of contraception &amp; reproductive health care : the official journal of the European Society of Contraception</i> 18(6) 489–500. DOI:<a href=&quot;https://doi.org/10.3109/13625187.2013.822061&quot;>10.3109/13625187.2013.822061</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23944295/&quot;>https://pubmed.ncbi.nlm.nih.gov/23944295</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03AA06;
